NeuroSense Therapeutics Ltd. (NRSN)

NCM – Real vaqt narxi. Valyuta: USD

0.76

-0.00 (-0.21%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

0.76

0.00 (0.00%)

Bozordan keyin: Jun 26, 2026, 4:04 PM EDT

11.06.2026

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United States Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC CAMBRIDGE, Mass., June 11, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

09.06.2026

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents CAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

28.04.2026

NeuroSense Announces Pricing of Insider-Led PIPE Financing

Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

06.04.2026

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

Patent Protection Through October 2042 Follows prior patent grants in the U.S. and Australia Further strengthens NeuroSense's global intellectual property portfolio CAMBRIDGE, Mass., April 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

03.04.2026

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirements The Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder value CAMBRIDGE, Mass., April 3, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

31.03.2026

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS Statistically significant survival benefit demonstrated, including 65% reduction in risk of death and >14-month median survival advantage Results published in JAMA Neurology, providing high-level peer-reviewed validation of clinical and biological activity Advancing toward key regulatory milestones with planned pre-NDS meeting in Canada and near-term Alzheimer's readout CAMBRIDGE, Mass., March 31, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

24.03.2026

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

Videolar

No Data

There is no data to display

Press-relizlar

11.06.2026

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

09.06.2026

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents CAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

28.04.2026

NeuroSense Announces Pricing of Insider-Led PIPE Financing

Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

06.04.2026

NeuroSense Therapeutics Ltd. (NRSN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

NeuroSense Therapeutics Ltd. (NRSN)

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NeuroSense Announces Pricing of Insider-Led PIPE Financing

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

Videolar

No Data

Press-relizlar

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NeuroSense Announces Pricing of Insider-Led PIPE Financing

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NeuroSense Announces Pricing of Insider-Led PIPE Financing

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

Videolar

No Data

Press-relizlar

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NeuroSense Announces Pricing of Insider-Led PIPE Financing

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

Search stocks

NeuroSense Therapeutics Ltd. (NRSN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

NeuroSense Therapeutics Ltd. (NRSN)

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NeuroSense Announces Pricing of Insider-Led PIPE Financing

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

Videolar

No Data

Press-relizlar

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NeuroSense Announces Pricing of Insider-Led PIPE Financing

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NeuroSense Announces Pricing of Insider-Led PIPE Financing

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

Videolar

No Data

Press-relizlar

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NeuroSense Announces Pricing of Insider-Led PIPE Financing

NeuroSense Granted Brazilian Patent Covering PrimeC Composition